Current obstructive sleep apnea (OSA) diagnosis methods, although often effective, all require the patient to be asleep ...

undiagnosed obstructive sleep apnea (OSA). With up to 90% of sleep-related breathing disorders going undiagnosed, Vivos is pioneering a transformative approach with the Vivos Method—a patient ...

Vivos Therapeutics (NASDAQ:VVOS) stock was up 6% in premarket trading Tuesday after the company said its CARE medical devices for the treatment of sleep apnea have been approved for reimbursement ...

Vivos announces immediate expansion of its new alliance model into two additional Colorado locations as initial reports show sleep apnea patients prefer Vivos CARE treatment for OSA nearly 2 to 1 ...

the risk that some patients may not achieve the desired results from using Vivos’ products, (iii) risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea treatment ...

Vivos Therapeutics medical devices include treatments for obstructive sleep apnea (OSA) in adults. The company notes that many of the 66.9 million enrolled in Medicare suffer from OSA. The current ...

The company said initial data from the partnership showed that patients prefer Vivos CARE as a treatment for obstructive sleep apnea (OSA) nearly two to one over continuous positive airway ...

Vivos announces immediate expansion of its new alliance model into two additional Colorado locations as initial reports show sleep apnea patients prefer Vivos CARE treatment for OSA nearly 2 to 1 ...

Inc. (“Vivos” or the“Company”) (NASDAQ: VVOS), a leader in novel, non-invasive obstructive sleep apnea (OSA) treatments, today announced several significant milestone achievements in its ...